Study of the antilymphoma activity of pracinostat reveals different sensitivities of DLBCL cells to HDAC inhibitors

Histone deacetylase inhibitors (HDACis) are antitumor agents with distinct efficacy in hematologic tumors. Pracinostat is a pan-HDACi with promising early clinical activity. However, similar to other HDACis, its activity as a single agent is limited. Diffuse large B-cell lymphoma (DLBCL) includes di...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Blood Adv
Hlavní autoři: Mensah, Afua Adjeiwaa, Spriano, Filippo, Sartori, Giulio, Priebe, Valdemar, Cascione, Luciano, Gaudio, Eugenio, Tarantelli, Chiara, Civanelli, Elisa, Aresu, Luca, Rinaldi, Andrea, Damia, Giovanna, Lovati, Emanuela, Zucca, Emanuele, Stathis, Anastasios, Pietra, Claudio, Bertoni, Francesco
Médium: Artigo
Jazyk:Inglês
Vydáno: American Society of Hematology 2021
Témata:
Lymphoid Neoplasia
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC8152508/
https://ncbi.nlm.nih.gov/pubmed/33999145
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2020003566
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky